Pharma Hopes EU Commission Policy Report Will Lead To Real Dialogue
This article was originally published in The Tan Sheet
The European Commission's latest policy document dedicated to making the pharma industry a better global competitor advocates a new, co-operative approach, but lacks detail. The industry, though, believes the document offers hope for constructive debate in key areas.
You may also be interested in...
Prices may decrease, but at least wider societal benefits are to be included in NICE’s assessment in the U.K.’s new value-based pricing (VBP) scheme for new pharmaceuticals, a change long demanded by critics of the health technology assessment body.
The EU Council of Ministers has finally settled on three locations for the Unified Patent Court, which will cut costs and litigation time for pharmaceutical companies.
EU Transparency Directive Revisions May Accelerate Access To New Medicines, But IP Issues Set To Cause A Storm
Proposed revisions to the EU Transparency Directive could drive faster access to medicines. But innovative product sponsors say IP rules will damage their business.